A Comparative Study of 5-ethyl-2′-Deoxyuridine and Selected Lipophilic 5,6-Dihydro Double/Triple Prodrugs
Open Access
- 1 December 1995
- journal article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 6 (6) , 356-364
- https://doi.org/10.1177/095632029500600602
Abstract
(+)- Trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-5′-O-valeryl-2′-deoxyuridine (3) and (+)- trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-3′,5′-di-O-valery[-2′-deoxyuridine (4) were synthesized in 55% and 8.6% yield, respectively, by esterification of the 5′-hydroxyl group of (+)- trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-2′-deoxyuridine (2) using valeryl chloride. [4-14C]-3 and [4-14C]-4 were synthesized in 79% and 64% chemical and radiochemical yield, respectively, by similar esterifications of [4-14C]-2. The double prodrug 3 was readily hydrolysed (> 95% in 8 min) to 5-ethyl-2′-deoxyuridine (EDU) by porcine liver esterase in vitro. The biotransformations of 2 and 3 were studied following i.v. injection of a 0.4 mmol/kg i.v. dose to male Balb/c mice. The single prodrug 2 was rapidly cleared (−1) than the AUC observed when EDU itself was injected (1.7 ± 0.2 μmol.h.g−1). The double prodrug 3 provided a sustained high concentration of EDU in blood, with an AUC for EDU, as a metabolite of 3, of 1.8 ± 0.2 μmol.hr.g−1. 5′-O-Valeryl-5-ethyl-2′-deoxyuridine and 3 were both detected in blood samples collected up to 35 min post i.v. injection. 5-Ethyluracil and 5-(1-hydroxyethyl)-uracil were identified as secondary metabolites of EDU, 2 and 3. Compared to [4-14C]-EDU, i.v. injection of [4-14C]-3 or [4-14C]-4 provided significantly higher (P < 0.001) radioactivity levels in the brain, but neither EDU, 2 or 3 protected mice against intracerebral herpes simplex virus infection. Hepatic uptakes of 2, 3 and 4, in mice, were similar to each other despite the respective substantial increases in both molecular weight and lipophilicity of this series. In rats, biliary excretion over the 0-4 h period after i.v. injection accounted for only 2.9-3.9% of the injected dose for these prodrugs.Keywords
This publication has 16 references indexed in Scilit:
- HERPES SIMPLEX VIRUS ENCEPHALITIS: PROBLEMS IN DIAGNOSISDevelopmental Medicine and Child Neurology, 1992
- Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivoAntimicrobial Agents and Chemotherapy, 1989
- The double prodrug concept and its applicationsAdvanced Drug Delivery Reviews, 1989
- Mechanism of Antiviral Activity of 5-Ethyl-2′-DeoxyuridineNucleosides and Nucleotides, 1987
- An improved synthesis of 14C-labelled 2,2′-anhydrouridine, 2′-deoxyuridine and 5-ethyl-2′-deoxyuridineInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1986
- Prodrugs of 5‐Ethyl‐2′‐deoxyuridine, II Syntheses and Antiviral Activities of 5′‐ and 3′‐Ester DerivativesArchiv der Pharmazie, 1986
- Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2Antimicrobial Agents and Chemotherapy, 1983
- Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeabilityJournal of Medicinal Chemistry, 1980
- Excretion patterns of 125I-radioiodohippuric acid in normal and in chronically uremic ratsInternational Journal of Nuclear Medicine and Biology, 1978
- Notes. A Nonmutagenic Thymidine Analog with Antiviral Activity. 5-EthyldeoxyuridineJournal of Medicinal Chemistry, 1969